Cagrilintide

Cagrilintide is a long-acting amylin analog in development, showing promising results when combined with semaglutide (CagriSema). Amylin is a hormone co-secreted with insulin that promotes satiety.

Mechanism of Action

Activates amylin receptors (calcitonin receptor with RAMP proteins) to slow gastric emptying, suppress glucagon secretion, and reduce food intake through central satiety mechanisms distinct from GLP-1.

Typical Dosage (Research)

Clinical trials: 2.4mg weekly as monotherapy or in combination with semaglutide 2.4mg (CagriSema). Optimal dosing still being determined.

Subcutaneous injection once weekly. Currently only available in clinical trials - not yet FDA approved.

Side Effects & Risks

Nausea, vomiting, diarrhea, constipation similar to other incretin-based therapies. Combination with semaglutide may increase GI effects initially.

Investigational compound - full safety profile being established. Expected to carry similar warnings to approved amylin analog pramlintide.

Who Uses Cagrilintide

Currently clinical trial participants only. Expected to target those seeking enhanced weight loss beyond GLP-1 monotherapy.